Logan Capital Management’s AbbVie ABBV Stock Holding History

Logan Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.1M	Buy	+78,596	New	+$17.4M	0.74%	34

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Logan Capital Management's ABBV Position: Q1 2026 in Review

Logan Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 79,419 shares — an estimated $17.6M sold.

Logan Capital Management first reported a position in ABBV in Q3 2013 and held it in 50 quarters. The position peaked at $23.9M in Q1 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Logan Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Logan Capital Management sold 79,419 AbbVie shares in Q1 2026, an estimated $17.6M.
Logan Capital Management first reported a position in AbbVie in Q3 2013 and held it in 50 quarters.
Logan Capital Management's AbbVie position peaked at $23.9M in Q1 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Logan Capital Management's 13F filing for Q1 2026, filed 8 May 2026.